Research Article
Pharmacological Insights and Therapeutic Potential of Homotaurine in Neurological Disorders: A Review of Preclinical and Clinical Studies
@INPROCEEDINGS{10.4108/eai.13-11-2024.2355680, author={Surendra Vada and Rakshitha KB and Snehal Kodachawadkar and Manjunath P Mudgal and Uday Raj Sharma and Suresh Janadri and Haribabu T and Nageena Taj and Jyostna SK and Tanuja NK}, title={Pharmacological Insights and Therapeutic Potential of Homotaurine in Neurological Disorders: A Review of Preclinical and Clinical Studies}, proceedings={Proceedings of the 1st International Conference on Frontiers in Physical and Chemical Sciences: Exploring New Horizons, FPCS 2024, 13-14 November 2024, Bengaluru, Karnataka, India}, publisher={EAI}, proceedings_a={FPCS}, year={2025}, month={8}, keywords={homotaurine pharmacology neurological disorders alzheimer's disease mild cognitive impairment gaba-a-receptor agonist}, doi={10.4108/eai.13-11-2024.2355680} }- Surendra Vada
Rakshitha KB
Snehal Kodachawadkar
Manjunath P Mudgal
Uday Raj Sharma
Suresh Janadri
Haribabu T
Nageena Taj
Jyostna SK
Tanuja NK
Year: 2025
Pharmacological Insights and Therapeutic Potential of Homotaurine in Neurological Disorders: A Review of Preclinical and Clinical Studies
FPCS
EAI
DOI: 10.4108/eai.13-11-2024.2355680
Abstract
Homotaurine (Tramiprosate) is a naturally occurring amino sulfonate that exhibits structural similarities with GABA and Taurine. As a GABA-A receptor agonist, it regulates GABAergic activity and has strong neuroprotective properties. Homotaurine's mechanism of action involves reducing amyloid-beta (Aβ) aggregation, thereby mitigating Alzheimer's disease (AD) and mild cognitive impairment (MCI). It stabilizes Aβ monomers, inhibits oligomer formation, and reduces Aβ42 levels in the cerebrospinal fluid. Furthermore, homotaurine's antioxidant properties and its ability to penetrate blood-brain barrier enhance its therapeutic potential. Clinical and experimental research show that it improves cognitive function in Alzheimer's disease and mild cognitive impairment, improves cognitive performance in Parkinson's disease, and provides neuroprotection in diabetic and glaucomatous retinopathy. ALZ-801, an optimized prodrug, has higher absorption and tolerance than oral homotaurine. Further study is needed to support its efficacy across all neurological disorders. Overall, homotaurine is a versatile and promising candidate for treating several types of neurological disorders.
